Genmab announces that epcoritamab in combination with R-ICE therapy in the Phase Ib/II EPCORE NHL-2 trial demonstrated an overall response rate of 87 percent and a complete response rate of 65 percent in patients with relapsed/refractory DLBCL eligible for stem cell transplant. 65 percent of patients proceeded to transplant. The study, presented at EHA 2025, demonstrated a manageable safety profile with low-grade CRS and no treatment discontinuations due to adverse events.
Genmab's Epcoritamab shows high response rates in DLBCL study
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
NEWSLETTER
NEWS
AI-designed proteins are created in seconds
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
